Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients

Lung Cancer

Volumn 65, Issue 2, 2009, Pages 230-236

  Sun, Xinchen ^a   Li, Fan ^a   Sun, Ning ^a   Shukui, Qin ^b   Baoan, Chen ^a   Jifeng, Feng ^c   Lu, Cheng ^a   Zuhong, Lu ^a   Hongyan, Cheng ^a   YuanDong, Cao ^a   Jiazhong, Ji ^d   Yingfeng, Zhou ^d  

^a SOUTHEAST UNIVERSITY   (China)

^b The 81st Hospital of PLA   (China)

^c JIANGSU CANCER HOSPITAL   (China)

^d Jiangbei People Hospital   (China)

Author keywords

Chemotherapy; Gene chip microarrays; Non small cell lung cancer (NSCLC); Single nucleotide polymorphism; XPG; XRCC1

Indexed keywords

ARGININE; ASPARTIC ACID; CARBOPLATIN; CISPLATIN; DNA; DOCETAXEL; GEMCITABINE; GLUTAMINE; HISTIDINE; NAVELBINE; NUCLEIC ACID BINDING PROTEIN; PACLITAXEL; PLATINUM DERIVATIVE; POLYACRYLAMIDE GEL; TRYPTOPHAN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP G PROTEIN; XRCC1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHINESE; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 67449162069     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.11.014     Document Type: Article

References (42)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer Statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J Clin 52 (2002) 23-47
3. Bunn P.A., and Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4 (1998) 1087-1100
4. Stephens J.R., Fairlamb D., Gower N., Maslove L., Milroy R., Napp V., et al. The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC)-preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 21 (2002) [abstr 1161]
5. Giaccone G. Clinical perspectives on platinum resistance. Drugs 59 (2000) 9-17
6. Johnson S.W., Stevenson J.P., and O'Dwyer P.J. Cisplatin and its analogues. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 6 ed. (2001), Lippincott Williams and Wilkins, Philadelphia, PA 376-388
7. Jordan P. Carmo-Fonseca M: molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57 (2000) 1229-1235
8. van de Vaart P.J.M., Belderbos J., de Jong D., Sneeuw K.C.A., Majoor D., Bartelink H., et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89 (2000) 160-166
9. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K., and Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62 (2002) 4899-4902
10. Reed E. Platinum-DNA adducts nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24 (1998) 331-344
11. de Boer J., and Hoeijmakers J.H. Nucleotide excision repair and human syndromes. Carcinogenesis 21 (2000) 453-460
12. Abdel-Rahman S.Z., and El-Zein R.A. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159 (2000) 63-71
13. Au W.W., Navasumrit P., and Ruchirawat M. Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health 207 (2004) 301-313
14. Auranen A., Song H., Waterfall C., Richard A., DiCioccio, Kuschel B., Kjaer S., et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 114 (2005) 611-618
15. Goode E.L., Ulrich C.M., and Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11 (2002) 1513-1530
16. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D., Wain J., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10 (2004) 4939-4943
17. Price N. Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. Clin Lung Cancer 6 (2004) 79-82
18. Chang-Claude J., Popanda O., Tan X.L., Kropp S., Helmbold I., Fournier D., et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 11 (2005) 4802-4809
19. Duell E.J., Wiencke J.K., Cheng T.J., Andrea Varkonyi, Zuo Z.F., Ashok T.D., et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21 (2000) 965-971
20. Lunn R.M., Langlois R.G., Hsieh L.L., Claudia L., Thompson, Douglas A., et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59 (1999) 2557-2561
21. Weaver D.A., Crawford E.L., Warner K.A., Elkhairi F., Khuder S., Willey J., et al. ABCC5, ERCC2 XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 4 (2005) 18
22. Aboussekhra A., Biggerstaff M., Shivji M.K., Vilpo J.A., Moncollin V., Podust V.N., et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 80 (1995) 859-868
23. Wakasugi M., Reardon J.T., and Sancar A. The non-catalytic function of XPG protein during dual incision in human nucleotide excision repair. J Biol Chem 272 (1997) 16030-16034
24. Jeon H.S., Kim K.M., Park S.H., Lee S.Y., Choi J.E., Lee G.Y., et al. Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer. Carcinogenesis 24 (2003) 167721681
25. Cheng L., Spitz M.R., Hong W.K., and Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 21 (2000) 1527-1530
26. Vila J.M., Moreno I., Monzo M., Ibeas R., Moreno J., Pinuaga M., et al. XPD, XPA ERCC1 and XPG/ERCC5 single nucleotide polymorphisms (SNPs) in oxaliplatin2treated colorectal cancer (CRC). J Clin Oncol 22 (2004) 3677
27. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
28. Xiao P.F., Cheng L., Wan Y., Sun B.L., Chen Z., Zhang S.Y., et al. An improved gel-based DNA microarray method for detecting single nucleotide mismatch. Electrophoresis 27 (2006) 3904-3915
29. Chen H.-Y., Yu S.-L., Chen C.-H., Chang G.-C., Chen C.-Y., Yuan A., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356 (2007) 11-20
30. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
31. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 13 (2001) 3210-3218
32. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 21 (2002) 4285-4291
33. Zatloukal P., Petruzelka L., Zemanová M., Kolek V., Skricková J., Pesek M., et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 41 (2003) 321-331
34. Efferth T., and Volm M. Pharmacokinetics for individualized cancer chemotherapy. Pharmacol Therap 107 (2005) 155-176
35. Thompson L.H., and West M.G. XRCC1 keeps DNA from getting stranded. Mutat Res 459 (2000) 1-18
36. Vila J.M., Moreno I., MonzoM R., Ibeas J., Moreno M., Pinuaga, et al. XPD, XPA, ERCC1 and XPG/ERCC5 single nucleotide polymorphisms (SNPs) in oxaliplatin treated colorectal cancer (CRC). J Clin Oncol 22 (2004) 3677
37. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum Chemotherapy. J Clin Oncol 22 (2004) 2594-2601
38. Giachino D.F., Ghio P., Regazzoni S., Mandrile G., Novello S., et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13 (2007) 2876-2881
39. Wang Y., Zhang D., Zheng W., Luo J., Bai Y., and Lu Z. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112 (2008) 61325-61336
40. Wan Y., Wang Y., Luo J., and Lu Z. Bisulfite modification of immobilized DNAs for methylation detection. Biosensors and Bioelectronics 22 (2007) 2415-2421
41. Xiao1 P.F., Cheng L., Wan Y., Sun B.L., Chen Z.Z., Zhang S.Y., et al. Gel immobilization of acrylamide-modified single-stranded DNA template for pyrosequencing. Electrophoresis 28 (2007) 1903-1912
42. Blommaert F.A., van Dijk-Knijnenburg H.C., Dijt F.J., den Engelse L., Baan R.A., Berends F., et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34 (1995) 8474-8480